Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are thirteen (13) LD deals that have been publicly confirmed subsequent to their approvals.
Orsini Specialty Pharmacy to Distribute Sephience
Orsini has been chosen by PTC Therapeutics as a specialty pharmacy partner for Sephience (sepiapterin), an FDA-approved oral therapy indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU).
Orsini Specialty Pharmacy to Exclusively Distribute Dawnzera
Orsini Specialty Pharmacy announced that it has been named the exclusive specialty pharmacy partner for Ionis Pharmaceuticals’ Dawnzera , an FDA-approved prophylactic medicine to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, self-administered via subcutaneous auto-injector.
Onco360 Specialty Pharmacy to Distribute Lynozyfic
Onco360 Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Onco360 Specialty Pharmacy to Distribute Modeyso
Onco360 Specialty Pharmacy has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.
Onco360 Specialty Pharmacy to Distribute Hernexeos
Onco360 Specialty Pharmacy has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos (zongertinib) approved for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TDK) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
Senderra Specialty Pharmacy to Distribute Ebglyss
Senderra Specialty Pharmacy has been selected as a national pharmacy partner by Lilly to distribute Ebglyss (lebrikizumab-lbkz), Lilly’s first-line biologic treatment for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg, who are not well controlled with prescription topical therapies, or who cannot use topical therapies.
PANTHERx Rare Pharmacy to Distribute Brinsupri
PANTHERx Rare Pharmacy was selected by Insmed as part of the network of specialty pharmacies to dispense Brinsupri (brensocatib), a once daily oral medication to treat non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.
Maxor Specialty Pharmacy to Distribute Brinsupri
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.
Amber Specialty Pharmacy to Distribute Brinsupri
Amber Specialty Pharmacy was selected by Insmed to be a limited distribution provider of Brinsupri. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.
Option Care Health to Distribute and Administer dexamethasone sodium phosphate (eDSP)
Quince Therapeutics Inc., selected Option Care Health as lead specialty infusion therapy provider for suites across the U.S. This strategic relationship will support the commercial development and launch of encapsulated dexamethasone sodium phosphate (eDSP) in the U.S.,
Walgreens Specialty Pharmacy to Distribute
Yeztugo (lenacapavir), manufactured by Gilead, is the first and only FDA-approved twice-yearly option for HIV prevention as of August 2025.
Nemluvio (nemolizumab), manufactured by Galderma, is approved for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. It is also approved to treat adults with prurigo nodularis.
Imkeldi (imatinib), manufactured by Shorla Oncology, is approved to treat certain forms of leukemia and other cancers.
